ライフサイエンスコーパス: diphtheria

1 ed to assist clinicians in managing clinical diphtheria.

2 antitoxin (DAT), the standard treatment for diphtheria.

3 diphtheriae is a human pathogen that causes diphtheria.

4 rtions of adults are becoming susceptible to diphtheria.

5 vaccines have prevented 40 million cases of diphtheria, 35 million cases of measles, and a total of

6 tussis immunization using a tetanus/low-dose diphtheria/5-component acellular-pertussis/inactivated-p

7 The effect a maternal tetanus, diphtheria, acellular pertussis (Tdap) vaccine booster b

8 Tdap (adolescent and adult tetanus, reduced diphtheria, acellular pertussis) vaccine.

9 13-25) vs third-trimester (>/=GW 26) tetanus-diphtheria-acellular pertussis (Tdap) immunization in pr

10 ality in high-income countries using tetanus-diphtheria-acellular pertussis (Tdap) vaccines in their

11 ants born to mothers vaccinated with tetanus-diphtheria-acellular pertussis (Tdap)-vaccine during pre

12 012, the scheduled administration of tetanus/diphtheria/acellular pertussis and meningococcal vaccine

13 We summarize the epidemiology of respiratory diphtheria and diphtheria-like illness and describe DAT

14 Antibodies to diphtheria and some CRM-conjugated antigens were also lo

15 nological and gestational age and receipt of diphtheria and tetanus toxoids and acellular pertussis v

16 ildhood and adolescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis,

17 ne children (78%) had received >/=3 doses of diphtheria and tetanus toxoids and aP vaccine at the tim

18 ntrations of PFASs and of antibodies against diphtheria and tetanus were measured and were compared w

19 er delivery in women immunized with tetanus, diphtheria, and acellular pertussis (Tdap) after the 20t

20 ed the association between prenatal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination a

21 women are recommended to receive a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine at 27

22 Women are recommended to receive tetanus, diphtheria, and acellular pertussis (Tdap) vaccine at th

23 nts born to mothers vaccinated with tetanus, diphtheria, and acellular pertussis (Tdap) vaccine durin

24 ion Practices (ACIP) recommends the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine for p

25 ountries have recommended universal tetanus, diphtheria, and acellular pertussis immunisation during

26 ernal vaccination with tetanus, reduced-dose diphtheria, and acellular pertussis vaccine (Tdap) could

27 coccal; tetanus and diphtheria; and tetanus, diphtheria, and acellular pertussis vaccines.

28 Thirty infants of Tdap (tetanus, diphtheria, and acellular pertussis)-vaccinated pregnant

29 posure to pyriproxyfen or vaccines (tetanus, diphtheria, and acellular pertussis, measles and rubella

30 o 6-year-olds was high for measles, rubella, diphtheria, and tetanus (91%-98%; 95% confidence interva

31 ate seroprotection against measles, rubella, diphtheria, and tetanus, using Luminex multiplex bead as

32 GBS serotypes; 1 month postdose 3 (D127) for diphtheria; and 1 month postprimary (D127) and postboost

33 easonal influenza; pneumococcal; tetanus and diphtheria; and tetanus, diphtheria, and acellular pertu

34 rium diphtheriae and C. ulcerans, and use of diphtheria anti-toxin in the United States, 1996-2018.

35 xposure at 7 y was associated with losses in diphtheria antibody concentrations at 13 y of 10-30% for

36 Diphtheria antibody concentrations decreased at elevated

37 CDC) for species and toxin confirmation, and diphtheria antitoxin (DAT) is obtained from CDC for trea

38 of data on the administration and safety of diphtheria antitoxin (DAT), the standard treatment for d

39 be treated with the timely administration of diphtheria antitoxin and antimicrobial therapy.

40 ation of infection, they must be paired with diphtheria antitoxin to limit morbidity.

41 Diphtheria antitoxin was issued in two (9.5%) cases; bot

42 n polyclonal horse sera directed against DT (diphtheria antitoxin; DAT).

43 toxoids (Td), compared to a licensed tetanus-diphtheria-aP vaccine containing chemically detoxified P

44 e population was seropositive to tetanus and diphtheria as defined by a protective serum antibody tit

45 >/=95% of infants were seroprotected against diphtheria at D127 and >/=91% of infants had seroprotect

46 Therefore, an additional tetanus-diphtheria campaign may be warranted in MSs to address t

47 Diphtheria can be treated with the timely administration

48 Thousands of diphtheria cases are still reported annually from severa

49 ed by healthcare providers for 151 suspected diphtheria cases between 1997-2018, with an average of 1

50 ool to screen isolates and identify probable diphtheria cases directly from specimens.

51 We described respiratory diphtheria cases reported to the National Notifiable Dis

52 From 1996-2018, 14 respiratory diphtheria cases were reported to NNDSS.

53 In response to measles and diphtheria cases, first documented in September and Nove

54 Here, we report a case of fatal respiratory diphtheria caused by toxigenic C. diphtheriae resistant

55 escribe the case of a patient with cutaneous diphtheria caused by toxigenic Corynebacterium ulcerans

56 Scd3-Cre-induced, diphtheria chain A toxin-mediated depletion of sebaceous

57 Respiratory diphtheria, characterized by a firmly adherent pseudomem

58 port on the effect of adding a pertussis and diphtheria component to the tetanus vaccination program

59 uberculosis (Mycobacterium tuberculosis) and diphtheria (Corynebacterium diphtheriae).

60 NTTB isolates reinforces the viewpoint that diphtheria culture diagnostics continue to provide the m

61 Appropriate tools to confront diphtheria exist; however, accurate understanding of the

62 on will remain protected against tetanus and diphtheria for >/=30 years without requiring further boo

63 receiving host Treg depletion with the IL-2-diphtheria fusion protein (IL2DT), the rate was 27%, wit

64 For more than 125 years, the therapy against diphtheria has been based on polyclonal horse sera direc

65 ognised, beta-lactam resistance in toxigenic diphtheria has not been described.

66 Diphtheria has re-emerged over the past several years.

67 Changes in the epidemiology of diphtheria have been reported worldwide.

68 the vaccine-preventable diseases measles and diphtheria have spread throughout the region.

69 Diphtheria is a potentially fatal infection mostly cause

70 Diphtheria is a potentially fatal respiratory disease ca

71 Respiratory diphtheria is a toxin-mediated disease caused by Coryneb

72 Diphtheria is an infectious disease caused by Corynebact

73 Diphtheria is generally an acute respiratory infection,

74 In the United States, respiratory diphtheria is nationally notifiable: specimens from susp

75 e illness, clinically indistinguishable from diphtheria, is caused by C. ulcerans, a zoonotic bacteri

76 ly, Corynebacterium pseudotuberculosis While diphtheria laboratory confirmation requires culture meth

77 e epidemiology of respiratory diphtheria and diphtheria-like illness and describe DAT use during 1996

78 Five cases of respiratory diphtheria-like illness caused by toxigenic C. ulcerans

79 lance System (NNDSS) and C. ulcerans-related diphtheria-like illness identified through specimen subm

80 dental identification of C. ulcerans-related diphtheria-like illness suggests surveillance of this co

81 Diphtheria-like illness, clinically indistinguishable fr

82 ling adult cardiomyocytes in alphaDKRC::DTA (diphtheria) mice caused progressive worsening left ventr

83 Diphtheria, once a major cause of childhood morbidity an

84 y she had received four vaccinations against diphtheria, pertussis and tetanus, which contained gelat

85 ith receipt of the first and second doses of diphtheria, pertussis, and tetanus vaccine (ie, 6 and 10

86 r BCG, followed by a booster dose of tetanus-diphtheria-pertussis inactivated polio vaccine (Tdap) 3

87 ion (IIV3) at enrollment, and either tetanus-diphtheria-pertussis vaccination or IIV3 6 months later.

88 s with high-spatial resolution (5 x 5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and

89 hat administrative coverage with 3rd dose of diphtheria-pertussis-tetanus vaccine in the 107 high-ris

90 childhood measles, bacillus Calmette-Guerin, diphtheria-pertussis-tetanus, polio, and maternal tetanu

91 Recent outbreaks highlight the risk diphtheria poses when civil unrest interrupts vaccinatio

92 te ablation of myeloid cells using the human diphtheria receptor system (diphtheria toxin receptor [D

93 idelines for the public health management of diphtheria, released as final guidelines in March, 2015.

94 Respiratory diphtheria remains rare in the United States, and reques

95 were 3.6 and 0.35 IU/mL against tetanus and diphtheria, respectively.

96 ast century resulted in knowledge gaps about diphtheria's epidemiology, transmission, and control.

97 Rubella and diphtheria seroprotection in MSs were significantly lowe

98 t adult vaccination schedule for tetanus and diphtheria should be revisited.

99 ides clinical and public health guidance for diphtheria-specific preparedness and response.

100 The European Diphtheria Surveillance Network (EDSN) ensures the relia

101 with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lym

102 ountries improved coverage in three doses of diphtheria tetanus pertussis containing vaccine between

103 among those who had only received 1 dose of Diphtheria Tetanus whole cell Pertussis (DTwP).

104 IgG antibody levels against pertussis toxin, diphtheria, tetanus and 6 of 10 pneumococcal serotypes v

105 mponent of the tetanus toxoid present in the diphtheria, tetanus and pertussis (DTP) vaccine.

106 es analysis to examine trends in coverage of diphtheria, tetanus, and pertussis (DTP) vaccination acr

107 with the third dose of a vaccine containing diphtheria, tetanus, and pertussis antigens (DTP3) was >

108 children who had received the third dose of diphtheria, tetanus, and pertussis vaccine were randomly

109 ) with a primary course only (three doses of diphtheria, tetanus, and pertussis vaccines [DTP3] comme

110 alongside pentavalent vaccine (which covers diphtheria, tetanus, and whole-cell pertussis; hepatitis

111 hemagglutinin (FHA), fimbriae 2 + 3 (FIMs), diphtheria, tetanus, Hib, MCC and PCV13 serotypes were c

112 red vaccines (routine), such as the standard diphtheria, tetanus, pertussis (DTP)-containing vaccine.

113 ere to receive OPV with pentavalent vaccine (diphtheria, tetanus, pertussis, Haemophilus influenzae t

114 of five infant vaccines: polio, pentavalent (diphtheria, tetanus, pertussis, hepatitis B virus, and H

115 pact estimates of childhood immunisation for diphtheria, tetanus, pertussis, hepatitis B, Haemophilus

116 ella, and immunogenicity of postchemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and

117 Plasma IgG levels specific for diphtheria, tetanus, pertussis, measles, rubella, and Ha

118 ion schedule was inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus i

119 tor: 10% annual improvement in third dose of diphtheria- tetanus-pertussis-containing vaccine (DTP3)

120 Three primary doses of the diphtheria-tetanus toxoids-acellular pertussis-inactivat

121 ns of an immuno-agent along with a pertussis-diphtheria-tetanus triple vaccine for autoimmune CP/CPPS

122 d in England, 1 year after the program using diphtheria-tetanus-5-component acellular pertussis-inact

123 hypothesis that delay in vaccines containing diphtheria-tetanus-acellular pertussis (DTaP) is associa

124 h 15 months who received at least 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the en

125 o adolescent cohorts that received different diphtheria-tetanus-acellular pertussis vaccines (DTaP) d

126 mmunization: combination diphtheria vaccine (diphtheria-tetanus-acellular pertussis-inactivated polio

127 ts in the consistent limb group received the diphtheria-tetanus-acellular pertussis-inactived polio-H

128 d overall mortality has been described after diphtheria-tetanus-pertussis (DTP) vaccination in female

129 gnancy on infants' antibody responses to the diphtheria-tetanus-pertussis (DTP) vaccine included in t

130 would be co-administered with either BCG or diphtheria-tetanus-pertussis (DTP)1; and the second or t

131 including delivery at the time of the first diphtheria-tetanus-pertussis vaccine (DTP1) or the first

132 ate-reported coverage with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3) to district-

133 d through the routine immunization schedule: diphtheria-tetanus-pertussis vaccine dose 1 (DTP1), DTP2

134 Programme of Immunisation (eg, BCG, measles, diphtheria-tetanus-pertussis, and three doses of polio)

135 d estimates of annual national third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) a

136 timates of the coverage of the third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3),

137 infections and death, as described following diphtheria-tetanus-whole cell pertussis (DTP) vaccinatio

138 ses, no significant differences in mean anti-diphtheria titres were detected across the supplement gr

139 29.4% (6.4-52.5; p = 0.012) higher mean anti-diphtheria titres, respectively.

140 ugars (OAg) of LPS to the nontoxic mutant of diphtheria toxin (CRM(197)).

141 (HiD); and the cross-reactive material from diphtheria toxin (CRM197).

142 Selective ablation of mitotic neurons using diphtheria toxin (DT) and a retrovirus vector encoding D

143 r 2 (eEF2) is the target of ADP ribosylating diphtheria toxin (DT) and Pseudomonas exotoxin A (PE).

144 However, diphtheria toxin (DT) crosses the blood-brain barrier, w

145 rated the first functional siRNA delivery by diphtheria toxin (DT) in vitro, marking an important ste

146 y timed local (subconjunctival) injection of diphtheria toxin (DT) into mice that express high-affini

147 nsists of interleukin 3 fused to a truncated diphtheria toxin (DT) molecule.

148 a gene knock-in strategy inserting the human diphtheria toxin (DT) receptor (DTR) into the endogenous

149 Hair cells express the human diphtheria toxin (DT) receptor behind the Pou4f3 promote

150 d in mature, transgenic mice where the human diphtheria toxin (DT) receptor was expressed behind the

151 neural crest-derived cells (ENCDCs) express diphtheria toxin (DT) receptor.

152 Administration of diphtheria toxin (DT) to these mice resulted in nearly c

153 Tg) mice but not in CLEC4C-DTR-Tg mice after diphtheria toxin (DT) treatment.

154 he throat and upper airways and the produced diphtheria toxin (DT), which binds to the elongation fac

155 glycemia after induction of a more complete, diphtheria toxin (DT)-induced beta-cell loss, a situatio

156 ed with CRE-dependent AAV vectors expressing diphtheria toxin (DTA) to selectively ablate FC SST neur

157 addition to Stx, the phage-encoded exotoxin, diphtheria toxin (Dtx) expressed by Corynebacterium diph

158 inating SCs followed by local application of diphtheria toxin (DTX).

159 an anti-CD25 immunotoxin (interleukin-2 with diphtheria toxin [IL-2-DT]), or two combinations of both

160 e, we present the design and validation of a diphtheria toxin A (DTA)-encoding lentiviral vector expr

161 GPAIS) challenge in rat insulin promoter and diphtheria toxin A (RIP-DTA) mice.

162 the lethal factor amino-terminal domain and diphtheria toxin A chain expedited translocation.

163 on was validated by assessing the effects of diphtheria toxin A chain expression.

164 on, utilizing temporally controlled targeted diphtheria toxin A expression, results in failure of neu

165 Interestingly, neutropenic lysozyme 2-diphtheria toxin A mice exhibited striking EG and amplif

166 s) via Cre-dependent viral expression of the diphtheria toxin A subunit (DT-A) in hemiparkinsonian tr

167 in mice for 25 d via neuronal expression of diphtheria toxin A-chain, producing both a neuroinflamma

168 ) cells, and donor Foxp3+ Treg depletion, by diphtheria toxin administration to DEREG donor mice whos

169 splantation carrying a conditional allele of diphtheria toxin alpha subunit and cell-specific express

170 utively ablated because of expression of the diphtheria toxin alpha subunit within developing DCs.

171 We found that diphtheria toxin and its nontoxic mutant, called CRM197,

172 teins that include the key virulence factors diphtheria toxin and the adhesive pili.

173 ction, reperfused myocardial infarction, and diphtheria toxin cardiomyocyte ablation), there is a shi

174 etane grafting of the genetically detoxified diphtheria toxin CRM197 improves significantly the immun

175 Injection of diphtheria toxin deleted YFP(+) cells from Foxl1-Cre;Ros

176 Some mice were given injections of diphtheria toxin during the recovery phase to delete Fox

177 ent of NFATc1-DTR mouse embryoid bodies with diphtheria toxin efficiently ablated endocardial cells,

178 To overcome this, Ucp1-Cre was used to drive diphtheria toxin expression in cells expressing UCP1 (Uc

179 ble cytoplasmic reconstitution of functional diphtheria toxin from engineered intein-flanked fragment

180 6 were culture-negative but PCR-positive for diphtheria toxin gene, 1 was culture-positive without fu

181 transformation method by the introduction of diphtheria toxin genes into the transformation vector as

182 family includes ADP-ribosyltransferases with diphtheria toxin homology (ARTD).

183 haDKRC::DTA mice that expressed an inducible diphtheria toxin in adult cycling cardiomyocytes and exa

184 Five days after administering diphtheria toxin in these adult mice, changes were obser

185 In these albumin-deficient rats, exposure to diphtheria toxin induced an increase in albumin GSC and

186 use, a model of hyperglycemia resulting from diphtheria toxin induced beta cell ablation.

187 tracer uptake in 2 models of cardiac injury (diphtheria toxin induced cardiomyocyte ablation and repe

188 model, PMN(DTR) mice, in which injection of diphtheria toxin induces selective neutrophil ablation.

189 and efficient depletion of Foxp3(+) Tregs by diphtheria toxin injection, we observed that transient F

190 nd that limited podocyte renewal occurs in a diphtheria toxin model of acute podocyte ablation.

191 and covalently linked to recombinant CRM197 diphtheria toxin mutant (CRM197) to produce CPS-CRM197.

192 hesized and attached via a chain linker to a diphtheria toxin mutant carrier protein.

193 calizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds

194 lls was assessed by selective depletion with diphtheria toxin or depleting anti-CD20 monoclonal antib

195 isting of interleukin-3 fused to a truncated diphtheria toxin payload.

196 Screens for sensitivity to a cholera-diphtheria toxin provide broad insights into the mechani

197 Cs from LNs based on their expression of the diphtheria toxin receptor (DTR) directed by the gene enc

198 Many such models rely on transgenic diphtheria toxin receptor (DTR) expression driven by DC-

199 Conditional expression of diphtheria toxin receptor (DTR) is widely used for tissu

200 ular junction (NMJ) by using mice expressing diphtheria toxin receptor (DTR) preferentially in tSCs c

201 used several murine models, including BDCA-2-diphtheria toxin receptor (DTR) transgenic and IFN-alpha

202 cy to various APCs, together with the use of diphtheria toxin receptor (DTR) transgenic mouse strains

203 s were eliminated in newly generated SiglecH-diphtheria toxin receptor (DTR)-transgenic (Tg) mice but

204 el transgenic mouse model in which the human diphtheria toxin receptor (huDTR) is selectively express

205 using the human diphtheria receptor system (diphtheria toxin receptor [DTR]) expressed in Lysmd1-cre

206 cendants (Foxl1-Cre;Rosa(YFP/iDTR)-inducible diphtheria toxin receptor [iDTR] mice).

207 By using B6/Langerin-diphtheria toxin receptor chimeric mice and LC ablation,

208 To test this hypothesis, we used a diphtheria toxin receptor expression system to selective

209 at ablation of Paneth cells in mice, using a diphtheria toxin receptor gene inserted into the P-lysoz

210 nondiabetic mice conditionally expressing a diphtheria toxin receptor in mural cells.

211 Using Langerin-diphtheria toxin receptor mice and established mouse mod

212 ished hepatic metastases in transgenic CD11b-diphtheria toxin receptor mice by intrasplenic injection

213 etion of Treg during MCMV infection in Foxp3-diphtheria toxin receptor mice or in wild-type mice reca

214 Selective Treg ablation in Foxp3-diphtheria toxin receptor mice with ischemic cardiomyopa

215 g monocytes only in CCR2 promoter-controlled diphtheria toxin receptor mice, whereas neutrophil numbe

216 We used CD11b-diphtheria toxin receptor transgenic mice to transiently

217 Adult male wild-type C57BL/6 mice, Foxp3-diphtheria toxin receptor transgenic mice, and tumor nec

218 t C57BL/6-DEREG mice expressing a transgenic diphtheria toxin receptor under the Foxp3 promoter, tran

219 ndocardial-specific ablation model using the diphtheria toxin receptor under the regulatory elements

220 ing CD (cluster of differentiation) 169-DTR (diphtheria toxin receptor) and CCR2-DTR mice, we further

221 tein, cluster of differentiation 11c (CD11c)/diphtheria toxin receptor, and IL-17 receptor A(-/-) mic

222 donor mice whose Foxp3+ Treg cells expressed diphtheria toxin receptor, restored rejection with eithe

223 We developed a diphtheria toxin receptor-based strategy to selectively

224 1 knockout mice; DEREG mice, which express a diphtheria toxin receptor-enhanced green fluorescent pro

225 the number of macrophages in mice following diphtheria toxin receptor-mediated cell ablation of panc

226 mice expressing the CCR2 promoter-controlled diphtheria toxin receptor.

227 y podocyte-specific transgenic expression of diphtheria toxin receptor.

228 with iDTR mice carrying Cre-dependent human diphtheria toxin receptor.

229 d a combinatorial viral technique to express diphtheria toxin receptors in specific neuron population

230 Diphtheria toxin robustly depleted circulating monocytes

231 on of NTS PPG neurons by viral expression of diphtheria toxin subunit A substantially reduced active

232 izures were frequent, mice were treated with diphtheria toxin to ablate peri-insult generated newborn

233 Administration of diphtheria toxin to HBUS mice accelerated development of

234 We induced autonomous expression of diphtheria toxin to kill articular surface chondrocytes

235 switching in several systems, including the diphtheria toxin translocation (T) domain, which is resp

236 cdB and the well-characterized alpha-helical diphtheria toxin translocation domain provide insights i

237 In chimeric CD11c-DTR mice, diphtheria toxin treatment results in enhanced neutrophi

238 d to those conjugated to tetanus (TT) or the diphtheria toxin variant, CRM.

239 ectories of the conformational transition of diphtheria toxin, a particularly challenging example, sh

240 ted with increased fatality risk, are due to diphtheria toxin, an exotoxin produced by the pathogen t

241 detrimental effects of anthrax lethal toxin, diphtheria toxin, cholera toxin, Pseudomonas aeruginosa

242 Diphthamide, the target of diphtheria toxin, is a unique posttranslational modifica

243 After pericyte ablation with diphtheria toxin, mice showed acute blood-brain barrier

244 vidity of immunoglobulin (Ig) G specific for diphtheria toxin, pertussis toxin, filamentous hemagglut

245 Its name refers to the target function for diphtheria toxin, the disease-causing agent that, throug

246 Thus, in contrast to diphtheria toxin, the formation of a membrane-competent

247 ecifically ablated through administration of diphtheria toxin, we demonstrate that natural Tregs are

248 e lamina propria by injecting HBUS mice with diphtheria toxin, which binds transgenic HBEGF expressed

249 ono-ADP-ribosyltransferase proteins, such as diphtheria toxin, with the exception of a unique loop th

250 cific damage in mice of either sex either by diphtheria toxin-based ablation of >50% of mature DG gra

251 e used a transgenic mouse system that allows diphtheria toxin-based depletion of pericytes.

252 esponse and type 2 diabetes mellitus (T2DM), diphtheria toxin-expressing (DT) mice that specifically

253 Diphtheria toxin-induced depletion of Tregs significantl

254 microglia exert beneficial effects during a diphtheria toxin-induced neuronal lesion, but impede rec

255 Diphtheria toxin-mediated ablation of lysozyme M-positiv

256 answer this question, we used Cre-dependent, diphtheria toxin-mediated cell ablation to selectively r

257 Using a progressive, time-controllable, diphtheria toxin-mediated cell ablation/dysfunction tech

258 Using diphtheria toxin-mediated depletion models in mice, we s

259 AD(+)-dependent bacterial exotoxins, such as diphtheria toxin.

260 nsive islet infiltration upon treatment with diphtheria toxin.

261 immunity, only if Tregs were depleted using diphtheria toxin.

262 ma cells before depleting myeloid cells with diphtheria toxin.

263 , a zoonotic bacterium that can also produce diphtheria toxin.

264 e fused to the protein delivery machinery of diphtheria toxin.

265 nd specifically ablated by administration of diphtheria toxin.

266 ng of human interleukin-3 fused to truncated diphtheria toxin.

267 ogenic insult using a conditional, inducible diphtheria-toxin receptor expression strategy in mice.

268 Diphtheria-toxin receptor expression was induced among g

269 nction, we eliminated DCS cells by using the diphtheria-toxin receptor gene knocked into the murine R

270 Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin-based fusion protein that depletes CD25

271 educed vascular leak, is a second-generation diphtheria-toxin-based fusion protein with promise as a

272 Using Slc6a3(DTR/+) diphtheria-toxin-sensitive mice, we demonstrate that a p

273 ), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially

274 in the infants and their immune response to diphtheria toxoid and pneumococcal vaccination.

275 nd did not affect infant immune responses to diphtheria toxoid and pneumococcal vaccination.

276 nt meningococcal conjugate vaccine that uses diphtheria toxoid as the protein carrier (MCV4-DT).

277 ere then conjugated with the carrier protein diphtheria toxoid cross-reactive material (CRM) 197 (DT)

278 However, S2 conjugated to diphtheria toxoid is highly immunogenic and induces Abs

279 Three doses of diphtheria toxoid vaccine are 87% (95% CI, 68-97%) effec

280 mized to receive III-TT conjugate or tetanus diphtheria toxoid vaccine in a multicenter, observer-bli

281 Receipt of 3 doses of diphtheria toxoid vaccine is 87% (95% CrI, 68%-97%) effe

282 response, a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccin

283 al immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccin

284 recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap

285 single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine).

286 nt women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine.

287 In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was

288 (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis; and

289 s documented; (6) neonatal immunization with diphtheria toxoid, tetanus toxoid, and acellular pertuss

290 agglutinin (FHA) coadministered with tetanus-diphtheria toxoids (Td), compared to a licensed tetanus-

291 t the Medecins Sans Frontieres Rubber Garden Diphtheria Treatment Center from December 2017-September

292 organism commonly associated with cutaneous diphtheria, usually seen as an imported tropical disease

293 ization schedules recommend that tetanus and diphtheria vaccination be performed every 10 years.

294 s received routine immunization: combination diphtheria vaccine (diphtheria-tetanus-acellular pertuss

295 ll but disappeared following introduction of diphtheria vaccine.

296 acellular pertussis, inactivated polio, and diphtheria vaccines at 12 to 24 months of age.

297 Diphtheria was diagnosed based on the WHO clinical case

298 11-17 years), whereas antibody responses to diphtheria were more long-lived and declined with an est

299 xist among children in MSs, particularly for diphtheria, which requires serial vaccinations to achiev

300 Respiratory diphtheria with the absence of a pharyngeal membrane was